Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Treating major depression is a medical need that remains unmet by monoaminergic
therapeutic strategies that commonly fail to achieve symptom remission. A breakthrough in …

Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-
based antidepressant drugs are a primary line of treatment for this mental disorder, although …

Ketamine treatment decreases depressive symptoms within hours, but the mechanisms
mediating these rapid antidepressant effects are unclear. Here, we demonstrate that activity …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

The discovery of the rapid antidepressant effects of the dissociative anaesthetic ketamine,
an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is arguably the most important …

Major depressive disorder has become a global public health problem of serious concern.
Most of the clinical antidepressants are developed under the classic “monoamine …

Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the
many hypotheses proposed to understand the molecular pathophysiology of depression, it is …